Cancer continues to inflict devastating consequences worldwide. Initially Bexion was founded to develop innovative treatments for cancer. Bexion is currently running a Phase 2 clinical trial for a rare pediatric brain tumor (Diffuse Intrinsic Pontine Glioma-DIPG) and plans to initiate two additional adult Phase 2 programs in 2021. A Phase I, all-comers solid tumor trial evidenced an extremely compelling toxicity and tolerability profile. The Phase 1 program also demonstrated preliminary single agent evidence of activity across a range of tumors. As BXQ-350 targets ubiquitous solid tumor features, antitumor effects have been documented across a range of solid tumors, including brain tumors. BXQ-350’s broad anti-tumor activity reflects its involvement in multiple pathways potentially representing universal tumor physiologies. Further, it shows activity in tumor cell lysosomes, and targets externalized phosphatidylserine (PS), another tumor agonistic onco-marker. In vitro studies show BXQ-350 catalyzes various cellular processes, including apoptosis, necrosis and other cellular death pathways consistent with activity at the lysosome. Preclinical and clinical data are supporting identification of a mechanism-based biomarker for BXQ-350 activity.
Bexion Pharmaceuticals is a clinical‐stage biopharmaceutical company pioneering the development of life‐changing treatments by leveraging the crucial cellular mechanisms of the lysosome. Bexion believes the lysosome is an underexploited cellular orchestrator involved in multiple diseases. Bexion’s lead drug candidate is BXQ‐350, a first‐in‐class biologic containing the multifunctional, lysosomal activator protein, Saposin C in a nanovesicle formulation. Initial development focused on an innovative, targeted cancer therapy platform. Preclinical and clinical data provide evidence of activity outside of a cancer therapeutic. Bexion is attempting to diversify its treatment portfolio to not only study and treat numerous types of cancer, but also neurodegenerative and infectious diseases as well, utilizing its novel compound, BXQ-350. The goal is to compile additional pre-clinical and clinical data on this drug to better elucidate mechanism of action, biomarker development, and demonstration of potential efficacy in a variety of disease conditions.